Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;99(3):149-155.
doi: 10.1136/sextrans-2022-055439. Epub 2022 May 18.

Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study

Affiliations

Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study

Vita W Jongen et al. Sex Transm Infect. 2023 May.

Abstract

Background: In many countries, HIV pre-exposure prophylaxis (PrEP) users are screened quarterly for STIs. We assessed the consequences of less frequent STI testing. We also assessed determinants of asymptomatic STI and potential for onward transmission.

Methods: Using data from the AMPrEP study, we assessed the proportion of syphilis, and genital, anal, and pharyngeal chlamydia and gonorrhoea diagnoses which would have been delayed with biannual versus quarterly screening. We assessed the potential for onward transmission by examining reported condomless anal sex (CAS) in periods after to-be-omitted visits when screening biannually. We assessed determinants of incident asymptomatic STIs using Poisson regression and calculated individual risk scores on the basis of the coefficients from this model.

Results: We included 366 participants. Median follow-up was 47 months (IQR 43-50). 1,183STIs were diagnosed, of which 932(79%) asymptomatic. With biannual screening, 483 asymptomatic STIs (52%) diagnoses would have been delayed at 364 study visits. Of these visits, 129 (35%), 240 (66%) and 265 (73%) were followed by periods of CAS with steady, known casual or unknown casual partners, respectively. Older participants had a lower risk of asymptomatic STI (incidence rate ratio (IRR) 0.86/10-year increase, 95% CI 0.80 to 0.92), while CAS with known (IRR 1.36, 95% CI 1.10 to 1.68) and unknown (IRR 1.86, 95% CI 1.48 to 2.34) casual partners and chemsex (IRR 1.51, 95% CI 1.28 to 1.78) increased the risk. The individual risk scores had limited predictive value (sensitivity=0.70 (95% CI 0.66 to 0.74), specificity=0.50 (95% CI 0.48 to 0.51)).

Conclusion: Reducing the STI screening frequency to biannually among PrEP users will likely result in delayed diagnoses, potentially driving onward transmission. Although determinants for asymptomatic STIs were identified, predictive power was low.

Keywords: Chlamydia Infections; NEISSERIA GONORRHOEAE; PREP; Pre-Exposure Prophylaxis; SYPHILIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The Public Health Service of Amsterdam received the drugs for the Amsterdam PrEP Study from Gilead Sciences based on an unconditional grant. UD received unrestricted research grants and speaker fees from Gilead Sciences, paid to his institute. HdV received grants from Medigene, and advisory board and speaker fees from Gilead Sciences, Medigene, Abbvie, Janssen-Cilag and Willpharma, all paid to his institute. MP received unrestricted research grants and speaker fees from Gilead Sciences, Roche, Abbvie and MSD, all paid to her institute. All other authors declare no competing interest.

Figures

Figure 1
Figure 1
Proportion of bacterial STI diagnoses that would have been delayed and that would not have been delayed if screening was done biannually rather than quarterly. Ct, Chlamydia trachomatis; Ng, Neisseria gonorrhoeae.
Figure 2
Figure 2
Incidence rate per 100 person-years (PY) of chlamydia, gonorrhoea and syphilis among PrEP users at all visits and at scheduled study visits only, AMPrEP cohort study, August 2015–February 2020, Amsterdam, the Netherlands. The week 54 visit was excluded due to the small number of participants who attended this visit. AMPrEP, Amsterdam PrEP demonstration project; PrEP, pre-exposure prophylaxis.

References

    1. Fonner VA, Dalglish SL, Kennedy CE, et al. . Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016;30:1973–83. 10.1097/QAD.0000000000001145 - DOI - PMC - PubMed
    1. Molina J-M, Capitant C, Spire B, et al. . On-Demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237–46. 10.1056/NEJMoa1506273 - DOI - PubMed
    1. Blumenthal J, Haubrich RH. Will risk compensation accompany pre-exposure prophylaxis for HIV? Virtual Mentor 2014;16:909–15. 10.1001/virtualmentor.2014.16.11.stas1-1411 - DOI - PMC - PubMed
    1. Vuylsteke B, Reyniers T, De Baetselier I, et al. . Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc 2019;22:e25407. 10.1002/jia2.25407 - DOI - PMC - PubMed
    1. Traeger MW, Schroeder SE, Wright EJ, et al. . Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis 2018;67:676–86. 10.1093/cid/ciy182 - DOI - PubMed

Publication types

MeSH terms